Comparison of pharmacokinetics of danofloxacin and enrofloxacin in calves challenged with Mannheimia haemolytica

American Journal of Veterinary Research

Volumn 66, Issue 2, 2005, Pages 342-349

  TerHune, Terry N ^a   Skogerboe, Terry L ^b   Shostrom, Valerie K ^b,c   Weigel, Daniel J ^b  

^a HMS Veterinary Development Inc   (United States)

^b PFIZER INC   (United States)

^c MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DANOFLOXACIN; ENROFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CATTLE; CATTLE DISEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; EUTHANASIA; GEOMETRY; LUNG PARENCHYMA; MALE; MANNHEIMIA HAEMOLYTICA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RANDOMIZATION; RESPIRATORY TRACT DISEASE; TISSUE DISTRIBUTION;

ANIMALS; ANTI-INFECTIVE AGENTS; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; FLUOROQUINOLONES; LUNG; MALE; MANNHEIMIA HAEMOLYTICA; MICROBIAL SENSITIVITY TESTS; PASTEURELLOSIS, PNEUMONIC; QUINOLONES;

ANIMALIA; BACTERIA (MICROORGANISMS); BOS TAURUS; BOVINAE; MANNHEIMIA HAEMOLYTICA;

EID: 14844286871     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.342     Document Type: Article

References (41)

1. Vancutsem PM, Babish JG, Schwark WS. The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 1990;80:173-186.
2. Giles CJ, Magonigle RA, Grimshaw WT, et al. Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J Vet Pharmacol Ther 1991;14:400-410.
3. Orsini JA, Perkons S. The fluoroquinolones: clinical applications in veterinary medicine. Compend Contin Educ Pract Vet 1992; 14:1491-1496.
4. Friis C. Penetration of danofloxacin into the respiratory tract tissues and secretions in calves. Am J Vet Res 1993;54:1122-1127.
5. Apley MD, Upson DW. Lung tissue concentrations and plasma pharmacokinetics of danofloxacin in calves with acute pneumonia. Am J Vet Res 1993;54:937-943.
6. Hamm M, Wollen T, Davidson J, et al. Clinical evaluation of enrofloxacin given as a single dose for the treatment of bovine respiratory disease, in Proceedings. 19th World Buiatrics Cong 1996; 58-60.
7. Brown SA. Fluoroquinolones in animal health. J Vet Pharmacol Ther 1996;19:1-14.
8. Hannan PC, Windsor GD, De Jong A, et al. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob Agents Chemother 1997;41:2037-2040.
9. Thomson PN, Van Amstel SR, Henton M. The clinical efficacy of enrofloxacin in the treatment of experimental bovine pneumonic pasteurellosis. Onderstepoort J Vet Res 1998; 65:105-112.
10. Norcia LJL, Silvia AM, Hayashi SF. Studies on time-kill kinetics of different classes of antibiotics against veterinary pathogenic bacteria including Pasteurella, Actinobacillus and Escherichia coli. J Antibiot 1999;52:52-60.
11. Lekeux P, Art T. Effect of enrofloxacin therapy on shipping fever pneumonia in feedlot cattle. Vet Rec 1988;123:205-207.
12. Yates WD. A review of infectious bovine rhinotracheitis, shipping fever pneumonia and viral-bacterial synergism in respiratory disease of cattle. Can J Comp Med 1982;46:225-263.
13. Madsen EB, Krogh HV, Ronsholt L, et al. Microbiological findings in nasal and lower respiratory tract samples of diseased calves, in Proceedings. 15th World Buiatrics Cong 1988;642-647.
14. Whiteley LO, Maheswaran SK, Weiss DJ, et al. Pasteurella haemolytica A1 and bovine respiratory disease: pathogenesis. J Vet Intern Med 1992;6:11-22.
15. Confer AW, Panciera Rf, Mosier DA. Bovine pneumonic pasteurellosis: immunity to Pasteurella haemolytica. J Am Vet Med Assoc 1988;193:1308-1316.
16. Confer AW, Clarke CR. Pasteurellosis in cattle. In: Howard JL, Smith RA, eds. Current veterinary therapy 4, food animal practice Philadelphia: WB Saunders Co, 1999;369-372.
17. Walker RD. Fluoroquinolones. In: Prescott JF, Baggot JD, Walker RD, eds. Antimicrobial therapy in veterinary medicine. 3rd ed. Ames, Iowa: Iowa State University Press, 2000;315-338.
18. Aliabadi FS, Lees P. Pharmacokmetic-pharmacodynamic integration of danofloxacin in the calf. Res Vet Sci 2003;74:247-259.
19. Mann DD, Frame GM. Pharmacokinetic study of danofloxacin in cattle and swine. Am J Vet Res 1992;53:1022-1026.
20. McKellar Q, Gibson I, Monteiro A, et al. Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. Antimicrob Agents Chemother 1999;43:1988-1992.
21. Sarasola P, Lees P, Aliabadi FS, et al. Pharmacokinetics and pharmacodynamic profiles of danofloxacin and enrofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella haemolytica). Antimicrob Agents Chemother 2002;46:3013-3019.
22. Nicolau DP, Quintiliani R, Nightingale CH. Antibiotic kinetics and dynamics for the clinician. Med Clin North Am 1995;79:477-495.
23. Meinen JB, McClure JT, Rosin E. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am J Vet Res 1995;56:1219-1224.
24. AliAbadi FS, Lees P. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation. Int J Antimicrob Agents 2000;14:307-313.
25. Highland R, Copeland D, Davidson J, et al. Dose determination and clinical evaluation of the efficacy of enrofloxacin injectable solution in the treatment of bovine respiratory disease, in Proceedings. 18th World Buriatrics Cong 1994;627-630.
26. Hamm M, Wollen T, Highland R, et al. Clinical efficacy of enrofloxacin against bovine respiratory disease comparing different treatment regimens. Bovine Pract 1999;33:56-59.
27. Kaartinen L, Salonen M, Alli L, et al. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular, and subcutaneous injections in lactating cows. J Vet Pharmacol Ther 1995; 18:357-362.
28. Friis C. Role of pharmacokinctics and phamacodynamics in the outcome of infections, in Proceedings. 16th Int Pig Vet Soc Cong 2000;82-84.
29. NCCLS. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved standard, NCCLS Document M31-A. Wayne, Pa: NCCLS, 1999.
30. Toutain PL, del Castillo JR, Bousquet-Melou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res Vet Sci 2002;73:105-114.
31. Walker RD, Hopkins FM, Schultz TW et al. Changes in leukocyte populations in pulmonary lavage fluids of calves after inhalation of Pasteurella haemolytica. Am J Vet Res 1985;46:2429-2433.
32. A180 sterile antimicrobial injectable solution. Freedom of information summary, NADA 141-207, Approved Sep 20, 2002.
33. Stegemann M, Wollen TS, Ewert KM, et al. Plasma pharmacokinetics of enrofloxacin administered to cattle at a dose of 7.5 mg/kg. J Vet Pharmacol Ther 1997;20(suppl 1):22.
34. Gunderson BW, Ross GH, Ibrahim KH, et al. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 2001;21:302S-318S.
35. Pickerill KE, Paladino JA, Schentag JJ, et al. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000;20:417-428.
36. Fremodt-Moller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 2002;19:333-339.
37. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-1060.
38. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998;27:33-39.
39. Schentag JJ, Nix DE, Forrest A. Pharmacodynamics of the fluoroquinolones. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. 2nd ed. Washington, DC: American Society of Microbiology, 1993;259-271.
40. Scaglione F. Can PK/PD be used in everyday clinical practice? Int J Antimicrob Agents 2002;19:349-353.
41. Baytril 100 injectable solution. Freedom of information summary, NADA 141-068, Approved Jul 24, 1998.